Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Project Details

StatusActive
Effective start/end date24/09/2031/03/26

Funding

  • Oslo University Hospital: AUD20,000.00
  • Oslo University Hospital: AUD20,000.00